<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615144</url>
  </required_header>
  <id_info>
    <org_study_id>17-596</org_study_id>
    <nct_id>NCT03615144</nct_id>
  </id_info>
  <brief_title>TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors</brief_title>
  <official_title>A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if removing a specific type of white blood cell&#xD;
      (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve&#xD;
      results of blood stem cell transplant for the participant's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Participant accrual low and the study was closed&#xD;
  </why_stopped>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Actual">November 13, 2020</completion_date>
  <primary_completion_date type="Actual">November 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>For this trial, patients will be assigned to receive one of two conditioning regimens, based on their disease, disease severity, organ status and history of red blood cell alloimmunization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Non-Malignant Hematologic Disorders</condition>
  <arm_group>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 70 mg/m2/day x 2</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa 7.5 mg/kg/day x 2</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Clofarabine 20-30 mg/m2/day x 5</description>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2/day x 5</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)</intervention_name>
    <description>antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CliniMACS reagents</intervention_name>
    <description>Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion Criteria:&#xD;
&#xD;
          -  Lethal disorders of Hematopoiesis correctable by transplant for which Alpha βeta&#xD;
             T-cell and CD-19 depleted allogeneic hematopoietic stem cell transplantation is&#xD;
             indicated including:&#xD;
&#xD;
          -  Sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+, HbSD, HbSE) with at least&#xD;
             one of the following criteria (Walters et al):&#xD;
&#xD;
               1. Cerebrovascular accident lasting longer than 24 hours&#xD;
&#xD;
               2. Impaired neuropsychological function with abnormal brain MRI/MRA&#xD;
&#xD;
               3. Recurrent hospitalizations (&gt;2 episodes/year over several years) or exchange&#xD;
                  transfusions for acute chest syndrome&#xD;
&#xD;
               4. Recurrent priapism&#xD;
&#xD;
               5. Stage I or II sickle chronic lung disease&#xD;
&#xD;
               6. Sickle cell nephropathy (moderate to severe proteinuria or glomerular filtration&#xD;
                  rate 30-50% of predicted normal value for age)&#xD;
&#xD;
               7. Bilateral proliferative retinopathy with major visual impairment in at least one&#xD;
                  eye&#xD;
&#xD;
               8. Osteonecrosis of multiple joints&#xD;
&#xD;
               9. Red cell alloimmunization during chronic transfusion therapy&#xD;
&#xD;
          -  Thalassemia major with at least one of the following criteria:&#xD;
&#xD;
               1. Age &lt;16 years&#xD;
&#xD;
               2. Available HLA-identical sibling&#xD;
&#xD;
               3. Red blood cell transfusion dependency&#xD;
&#xD;
               4. Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors:&#xD;
                  hepatomegaly, portal fibrosis, or poor response to chelation therapy)&#xD;
&#xD;
               5. Recurrence of disease after previous stem cell transplant&#xD;
&#xD;
          -  Bone Marrow Failure Syndromes:&#xD;
&#xD;
               1. Aplastic anemia refractory to immunosuppressive therapy&#xD;
&#xD;
               2. Diamond Blackfan Anemia refractory to conventional therapy&#xD;
&#xD;
               3. Shwachman-Diamond Syndrome&#xD;
&#xD;
               4. Severe Congenital Neutropenia&#xD;
&#xD;
               5. Congenital Amegakaryocytic Thrombocytopenia&#xD;
&#xD;
               6. Thrombocytopenia Absent Radii syndrome&#xD;
&#xD;
               7. Other marrow failure disorders not otherwise specified&#xD;
&#xD;
          -  Autoimmune cytopenias refractory to all conventional treatments&#xD;
&#xD;
               1. Autoimmune hemolytic anemia&#xD;
&#xD;
               2. Immune thrombocytopenia&#xD;
&#xD;
               3. Evan's syndrome&#xD;
&#xD;
               4. Pure red cell aplasia&#xD;
&#xD;
          -  Histiocytic disorders:&#xD;
&#xD;
               1. Hemophagocytic lymphohistiocytosis&#xD;
&#xD;
               2. High risk, recurrent or refractory Langerhans cell histiocytosis&#xD;
&#xD;
               3. Secondary HLH&#xD;
&#xD;
        Subject Inclusion Criteria:&#xD;
&#xD;
          -  Recipient's age birth to &lt; 70 years old&#xD;
&#xD;
          -  Patients must have adequate organ function measured by:&#xD;
&#xD;
          -  Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 50% and must&#xD;
             improve with exercise.&#xD;
&#xD;
          -  Hepatic: &lt; 3x ULN AST and ≤ 1.5 mg/dl total serum bilirubin, unless there is&#xD;
             congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused&#xD;
             by the disease in which the patient is receiving a transplant for. Patients with&#xD;
             higher bilirubin levels due to causes other than active liver disease are also&#xD;
             eligible with PI approval e.g. patients with PNH, Gilbert&quot;s disease or other hemolytic&#xD;
             disorders.&#xD;
&#xD;
          -  Pulmonary: asymptomatic or if symptomatic, DLCO ≥ 50% of predicted (corrected for&#xD;
             hemoglobin).&#xD;
&#xD;
          -  Renal: serum creatinine ≤1.5x normal for age. If serum creatinine is outside the&#xD;
             normal range, then CrCl &gt; 70 mL/min/1.73m2 (calculated or estimated) or GFR&#xD;
             (mL/min/1.72m2) &gt;30% of predicted normal for age.&#xD;
&#xD;
          -  Normal GFR in Children and Young Adults.&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  Each donor must meet criteria outlined by institutional guidelines and be medically&#xD;
             eligible to donate according to NMDP (or equivalent donor search organization)&#xD;
             criteria including testing for antibodies to Human TLymphotrophic Virus Types I &amp; II&#xD;
             (Anti-HTLV-I/II) and screening for West Nile Virus, Creutzfeldt-Jakob disease and&#xD;
             Zika.&#xD;
&#xD;
          -  Pediatric donors should weigh ≥ 25.0 kg, have adequate peripheral venous catheter&#xD;
             access for leukapheresis or must agree to placement of a central catheter.&#xD;
&#xD;
          -  Donor should be healthy and agree to receive G-CSF followed by donation of peripheral&#xD;
             blood stem cells.&#xD;
&#xD;
          -  Donors must agree to anesthesia and marrow donation (in cases of inadequate PBSC&#xD;
             collection).&#xD;
&#xD;
          -  Related or unrelated donors who are 7/8 or 8/8 HLA-antigen matched for haplotypes A,&#xD;
             B, C, DRB1 OR Related donors who are 4-6/8 HLA-antigen matched.&#xD;
&#xD;
        Subject Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Active viral, bacterial or fungal infection&#xD;
&#xD;
          -  Patient seropositive for HIV-I/II; HTLV-I/II&#xD;
&#xD;
          -  Karnofsky (adult)/Lansky (pediatric) &lt; 70%&#xD;
&#xD;
          -  Inherited DNA repair deficiency: Fanconi Anemia and Dyskeratosis Congenita. These are&#xD;
             presently undergoing transplantation based on a multi-center protocol&#xD;
&#xD;
          -  Patients with Thalassemia major with Pesaro risk score &gt;II&#xD;
&#xD;
          -  Inherited metabolic disorders: Hurler Syndrome, Sly syndrome (MPSVIII),&#xD;
             α-Mannosidosis, X- ALD, Osteopetrosis&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  Donors who are seropositive for HIV-I/II or HTLV-I/II and female patients who are&#xD;
             pregnant or breastfeeding will not be eligible for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Cancio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial SloanKettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <results_first_submitted>February 5, 2021</results_first_submitted>
  <results_first_submitted_qc>February 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-cell</keyword>
  <keyword>B-cell</keyword>
  <keyword>CliniMACS System</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Thiotepa</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>17-596</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03615144/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melphalan/Thiotepa/Clofarabine</title>
          <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Clofarabine: Clofarabine 20-30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
        </group>
        <group group_id="P2">
          <title>Melphalan/Thiotepa/ Fludarabine</title>
          <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Fludarabine: Fludarabine 30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participant no longer eligible for this protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participant accrual low and the study was closed.</population>
      <group_list>
        <group group_id="B1">
          <title>Melphalan/Thiotepa/Clofarabine</title>
          <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Clofarabine: Clofarabine 20-30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
        </group>
        <group group_id="B2">
          <title>Melphalan/Thiotepa/ Fludarabine</title>
          <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Fludarabine: Fludarabine 30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="20" upper_limit="20"/>
                    <measurement group_id="B3" value="20" lower_limit="20" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.</description>
        <time_frame>2 years</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Melphalan/Thiotepa/Clofarabine</title>
            <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Clofarabine: Clofarabine 20-30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
          </group>
          <group group_id="O2">
            <title>Melphalan/Thiotepa/ Fludarabine</title>
            <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Fludarabine: Fludarabine 30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Only 1 participants was accrued before the study was closed to accrual due to low accrual</desc>
      <group_list>
        <group group_id="E1">
          <title>Melphalan/Thiotepa/Clofarabine</title>
          <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Clofarabine: Clofarabine 20-30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
        </group>
        <group group_id="E2">
          <title>Melphalan/Thiotepa/ Fludarabine</title>
          <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.&#xD;
Melphalan: Melphalan 70 mg/m2/day x 2&#xD;
Thiotepa: Thiotepa 7.5 mg/kg/day x 2&#xD;
Fludarabine: Fludarabine 30 mg/m2/day x 5&#xD;
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.&#xD;
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, spec</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Cancio, MD</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-7196</phone>
      <email>canciom@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

